A nurse is caring for a client who is receiving high-dose metalopramide. The nurse should monitor the client for which of the following adverse effects?

A) Hematuria: Hematuria, or blood in the urine, is not typically associated with an allergic reaction to cefaclor. Instead, it may indicate other conditions such as urinary tract infection, kidney stones, or trauma to the urinary tract. While allergic reactions can affect the urinary system, hematuria is not a common manifestation.

B) Pruritus: Pruritus, or itching, is a classic symptom of an allergic reaction to medications, including antibiotics like cefaclor. Itching may occur on the skin or mucous membranes and can range from mild to severe. It is often accompanied by other allergic symptoms such as rash, hives, or swelling. Therefore, the presence of pruritus should alert the nurse to a potential allergic reaction to cefaclor.

C) Slurred speech: Slurred speech is not a typical manifestation of an allergic reaction to cefaclor. It is more commonly associated with neurological conditions, intoxication, stroke, or side effects of certain medications, rather than an allergic response to antibiotics.

D) Tremor: Tremor, or involuntary shaking, is not a characteristic sign of an allergic reaction to cefaclor. Tremors can have various causes, including neurological disorders, medication side effects, or metabolic abnormalities. While tremors can occur in severe allergic reactions (anaphylaxis), they are not among the primary symptoms.

A) PTT (Partial Thromboplastin Time): While the PTT is a laboratory test used to assess the intrinsic pathway of the coagulation cascade and monitor the effectiveness of heparin therapy, it is not routinely used to monitor warfarin therapy. Therefore, reviewing the PTT prior to administering warfarin is not necessary.

B) PT (Prothrombin Time): Prothrombin time measures the extrinsic pathway of the coagulation cascade and is commonly used to monitor warfarin therapy. Since warfarin works by inhibiting vitamin K-dependent clotting factors, such as factors II, VII, IX, and X, monitoring the PT allows for the assessment of the anticoagulant effect of warfarin and helps guide dosing adjustments. Therefore, reviewing the PT prior to administering warfarin is essential to ensure appropriate anticoagulation therapy.

C) WBC (White Blood Cell Count): The white blood cell count is not directly related to warfarin therapy monitoring. While an elevated white blood cell count may indicate infection, it is not specific to warfarin therapy and does not influence the administration of the medication.

D) Total iron-binding capacity: Total iron-binding capacity is a laboratory test used to assess iron status and is not relevant to monitoring warfarin therapy. It measures the body's ability to bind and transport iron in the blood, and its results are not indicative of warfarin's anticoagulant effect or dosage adjustments.